Results 11 to 20 of about 42,597 (192)

Development‐dependent expression of cyclin D3 in precursor T‐cell lymphoblastic leukemia/lymphoma [PDF]

open access: closedPathology International, 2007
In contrast to the clear oncogenic role of cyclins D1 and D2, cyclin D3 is suggested to have a role in the initiation and/or maintenance of differentiation in a lineage‐associated manner in addition to its basic role in proliferation. Recently, it has been reported that in cyclin D3‐deficient mice, normal expansion of T lymphocytes is impaired because ...
Eiichi, Sasaki   +7 more
  +5 more sources

Multi-Institution Review of Adult Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma (ETP-ALL)

open access: closedBlood, 2015
Abstract Background: The Early T-cell precursor (ETP) variant of acute lymphoblastic lymphoma/leukemia (ALL) is a recognized high risk variant, recognized by the absence of CD1a, with aberrant myeloid antigen expression (CD13, CD33, CD117, and CD34), and frequent absence of CD4 or CD8. Treatment intensification may improve
Bijal D. Shah   +6 more
openaire   +2 more sources

Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia

open access: goldHaematologica, 2010
Although deletions of cell cycle regulatory gene loci have long been reported in various malignancies, little is known regarding their relevance in pediatric T-cell lymphoblastic lymphoma (T-LBL) and T-cell lymphoblastic leukemia (TALL).
David Krieger   +6 more
doaj   +3 more sources

Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 Expression

open access: closedBlood, 2020
Introduction: T-cell acute lymphoblastic leukemia (T-ALL) originating from early T-cell precursors (ETP-ALL) has distinct immunophenotype (CD1a-CD8-CD5-/weak and positive for myeloid or stem-cell markers [My-HSC+]) and is associated with poor outcome with 5-year (yr) survival <25%. Some T-ALL cases are transcriptionally similar to
Kiyomi Morita   +19 more
openaire   +2 more sources

PB1754: HOMOZYGOUS DELETION OF ETV6: EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA OR PRECURSOR T-LYMPHOBLASTIC LYMPHOMA

open access: goldHemaSphere, 2023
Miguel Ángel Perera Álvarez   +10 more
doaj   +2 more sources

ABL oncogene amplification with p16INK4a gene deletion in precursor T‐cell acute lymphoblastic leukemia/lymphoma: Report of the first case [PDF]

open access: closedAmerican Journal of Hematology, 2004
AbstractGene amplification is a relatively rare event in hematologic malignancies. The ABL gene on chromosome band 9q34 is a proto‐oncogene and is the well‐known translocation partner of the BCR gene on 22q11 giving rise to t(9;22)(q34;q11), which is the hallmark of chronic myeloid leukemia and is the most common chromosomal abnormality in adult acute ...
Hee-Jin, Kim   +4 more
openaire   +3 more sources

Clonal Evolution and Lineage Switch from T-Cell Acute Lymphoblastic Leukemia to Acute Myeloid Leukemia in Therapy-Resistant <i>PICALM::MLLT10</i> Leukemia. [PDF]

open access: yesEJHaem
ABSTRACT Background PICALM::MLLT10‐positive T‐ALL is rare and associated with poor prognosis. Lineage switch to AML is exceptionally uncommon, particularly after long‐term remission. Case Presentation We report an adolescent PICALM::MLLT10‐positive T‐ALL with a cortical thymocyte, non‐ETP phenotype.
Kawamura M   +10 more
europepmc   +2 more sources

CBFA2T3::GLIS2‐positive acute leukemia with RAM and mixed T/megakaryocytic phenotype

open access: yeseJHaem, 2023
Herein, we present a rare case of acute myeloid leukemia (AML) with CBFA2T3‐rearrangement and the expression of megakaryocytic and lymphoid markers, highlighting the need for a high suspicion index in differential diagnosis and applying adequate workup ...
Mahsa Khanlari   +8 more
doaj   +1 more source

Inclusion of the Inducible Caspase 9 Suicide Gene in CAR Construct Increases Safety of CAR.CD19 T Cell Therapy in B-Cell Malignancies

open access: yesFrontiers in Immunology, 2021
T cells engineered with chimeric antigen receptor (CAR-T cells) are an effective treatment in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma.
Marika Guercio   +20 more
doaj   +1 more source

Home - About - Disclaimer - Privacy